Roehm PC, et al.
Prevalence of periocular depigmentation after repeated botulinum toxin A injections in African American patients. J Neuroophthalmol. 1999 Mar;19(1):7-9. PMID: 10098540; UI: 99196176.
Lee RE, et al. [See Related Articles]
Association of adhesive macromolecules with terminal sprouts at the neuromuscular junction after botulinum treatment. Otolaryngol Head Neck Surg. 1999 Feb;120(2):255-61. PMID: 9949361; UI: 99152641.
[See Related Articles]
Tan AK. Botulinum toxin for neurological disorders in a movement disorders clinic in Singapore. Singapore Med J. 1998 Sep;39(9):403-5. PMID: 9885719; UI: 99103105. [See Related Articles]
Song KH.
Botulinum toxin type A injection for the treatment of frown lines. Ann Pharmacother. 1998 Dec;32(12):1365-7. Review. PMID: 9876820; UI: 99094100. [See Related Articles]
Binder WJ, et al.
Treatment of hyperfunctional lines of the face with botulinum toxin A. Dermatol Surg. 1998 Nov;24(11):1198-205. Review. PMID: 9834739; UI: 99051804. [See Related Articles]
Grandas F, et al.
Blink reflex recovery cycle in patients with blepharospasm unilaterally treated with botulinum toxin. Clin Neuropharmacol. 1998 Sep-Oct;21(5):307-11. PMID: 9789711; UI: 99006140. [See Related Articles]
Anderson RL, et al.
Blepharospasm: past, present, and future. Ophthal Plast Reconstr Surg. 1998 Sep;14(5):305-17. PMID: 9783280; UI: 98456619.
[See Related Articles]
Van den Bergh PY, et al.
Dose standardization of botulinum toxin. Adv Neurol. 1998;78:231-5. No abstract available. PMID: 9750920; UI: 98423494. [See Related Articles]
Gusek-Schneider GC, et al.
[Protective ptosis by botulinum A toxin injection in corneal affectations]. Klin Monatsbl Augenheilkd. 1998 Jul;213(1):15-22. German. PMID: 9743934; UI: 98416576. [See Related Articles]
Boroojerdi B, et al.
Botulinum toxin treatment of synkinesia and hyperlacrimation after facial palsy. J Neurol Neurosurg Psychiatry. 1998 Jul;65(1):111-4. PMID: 9667571; UI: 98330145. [See Related Articles] Roser M, et al.
[New techniques in maxillofacial surgery: local injection treatment with botulinum toxin A]. Mund Kiefer Gesichtschir. 1998 May;2 Suppl 1:S121-4. German. PMID: 9658837; UI: 98322973. [See Related Articles]
Johnstone SJ, et al.
Headache and facial pain responsive to botulinum toxin: an unusual presentation of blepharospasm. Headache. 1998 May;38(5):366-8. PMID: 9630789; UI: 98294245. [See Related Articles]
Kowal L, et al.
Facial muscle spasms: an Australian study. Aust N Z J Ophthalmol. 1998 May;26(2):123-8. PMID: 9630292; UI: 98292246. [See Related Articles]
Mauriello JA Jr, et al.
Drug-associated facial dyskinesias--a study of 238 patients. J Neuroophthalmol. 1998 Jun;18(2):153-7. PMID: 9621275; UI: 98284295. [See Related Articles]
Laskawi R.
[Therapeutic use of botulinum toxin in otorhinolaryngology. 1: Treatment of movement disorders of mimetic muscles]. HNO. 1998 Mar;46(3):281-7. German. No abstract available. PMID: 9583037; UI: 98243872.
[See Related Articles]
Sampaio C, et al.
DYSBOT: a single-blind, randomized parallel study to determine whether any differences can be detected in the efficacy and tolerability of two formulations of botulinum toxin type A--Dysport and Botox--assuming a ratio of 4:1. Mov Disord. 1997 Nov;12(6):1013-8. PMID: 9399229; UI: 98061627. [See Related Articles]
Huber A.
[Use of botulinum toxin in ophthalmology]. Klin Monatsbl Augenheilkd. 1997 May;210(5):289-92. Review. German. PMID: 9324534; UI: 97374022.
[See Related Articles] Dodel RC, et al.
Costs of treating dystonias and hemifacial spasm with botulinum toxin A. Pharmacoeconomics. 1997 Dec;12(6):695-706. PMID: 10175981; UI: 98125225.
Wutthiphan S, et al.
Diplopia following subcutaneous injections of botulinum A toxin for facial spasms. J Pediatr Ophthalmol Strabismus. 1997 Jul-Aug;34(4):229-34. PMID: 9253737; UI: 97397698. [See Related Articles]
Scott AB.
Preventing ptosis after botulinum treatment. Ophthal Plast Reconstr Surg. 1997 Jun;13(2):81-3. PMID: 9185190; UI: 97328675. [See Related Articles] |
